:
Because that signal involves the gut, some people notice early changes like nausea, bloating, constipation, or a heavy feeling after meals
Semaglutide, a GLP-1 receptor agonist originally developed for diabetes, has become widely used for weight management because it reduces appetite and increases feelings of fullness
These conditions can include obesity, diabetes, hypertension, or heart disease
Researchers acknowledge that semaglutide helped to address problems of metabolic dysfunction that drive liver problems and holistically helped address liver disease and associated cardiometabolic illness. Its possible that the findings of this research are the result of weight loss
While we included a large number of RCTs overall in this study, for some drug groups, the meta-analysis results have been driven by only a few trials that carried greatest weight